Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation.
mutation
neoadjuvant therapy
niraparib
ovarian neoplasms
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
17
01
2023
accepted:
16
04
2023
medline:
5
7
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
This study analyzed a 63-year-old woman with hereditary BRCA1 mutation. She underwent interval debulking surgery after neoadjuvant chemotherapy for high-grade serous ovarian carcinoma (HGSOC). After 2 years of postoperative chemotherapy, she developed headache and dizziness, and a suspected metastatic cerebellar mass in left ovary was detected. Pathological analysis of the mass revealed HGSOC, which was removed surgically. Eight months and another 6 months after the surgery, local recurrence was noted; hence, she underwent CyberKnife treatment. After 3 months, cervical spinal cord metastasis was found, evidenced by left shoulder pain. Moreover, meningeal dissemination was present around the cauda equina. Chemotherapy treatment, including bevacizumab, was ineffective and increased lesions were observed. After CyberKnife treatment for the cervical spinal cord metastasis, niraparib was initiated for the meningeal dissemination. The cerebellar lesions and meningeal dissemination improved within 8 months of niraparib treatment. Although meningeal dissemination is challenging to treat, niraparib may be useful in BRCA-mutated HGSOC.
Substances chimiques
niraparib
HMC2H89N35
Indazoles
0
BRCA1 protein, human
0
BRCA1 Protein
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1875-1879Informations de copyright
© 2023 Japan Society of Obstetrics and Gynecology.
Références
Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;1870(1):103-19.
Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, et al. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget. 2018;9(98):37080-96.
Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48-54.
Diagnosis E, Borella F, Bertero L, Morrone A, Gambella A, Bovetti M, et al. Brain metastases from ovarian cancer: current evidence in diagnosis, treatment, and prognosis. Cancers (Basel). 2020;12(2156):1-22.
Ratner E, Bala M, Louie-gao M, Aydin E, Hazard S, Brastianos PK. Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. Gynecol Oncol. 2019;153(3):568-73.
Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients [Internet]. Cancer. 1982 [cited 2023 Apr 25]. p. 759-72. Available from: https://pubmed.ncbi.nlm.nih.gov/6895713/
Chang EL, Maor MH. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep. 2003;5(1):24-8.
Kim DY, Lee KW, Yun T, Park SR, Jung JY, Kim DW, et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol. 2003;33(12):608-12.
Jackman DM, Holmes AJ, Patrick NL, Wen Y, Kesari S, Borras AM, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal Metastases treated with high-dose Gefitinib. J Clin Oncol. 2006;24(27):4517-20.
Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009;4(11):1415-9.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709-22.
Zhan Q, Miao F, Huang R, Zhou X, Ge M, Liang X. Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis. J Thorac Dis. 2019;11(11):4725-34.
Sakamoto I, Hirotsu Y, Nakagomi H, Ikegami A, Teramoto K, Omata M. Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: a case report. J Obstet Gynaecol Res. 2019;45(3):743-7.
Gray S, Khor XY, Yiannakis D. Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. BMJ Case Rep. 2019;12(8):e230738.
Zhang Z, Xu M, Sakandar A, Du X, He H, He W. Successful treatment of a patient with brain metastasis from ovarian cancer with BRCA wild type using niraparib: a case report and review of the literature. Front Oncol. 2022;12:873198.